Arcellx Inc
NASDAQ:ACLX
US |
Fubotv Inc
NYSE:FUBO
|
Media
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
US |
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
|
CN |
NIO Inc
NYSE:NIO
|
Automobiles
|
|
US |
Fluor Corp
NYSE:FLR
|
Construction
|
|
US |
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
|
US |
TopBuild Corp
NYSE:BLD
|
Consumer products
|
|
US |
Abbott Laboratories
NYSE:ABT
|
Health Care
|
|
US |
Chevron Corp
NYSE:CVX
|
Energy
|
|
US |
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
|
US |
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
|
US |
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
|
US |
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
|
US |
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
48.05
106.53
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
Fubotv Inc
NYSE:FUBO
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
C
|
C3.ai Inc
NYSE:AI
|
US |
Uber Technologies Inc
NYSE:UBER
|
US | |
NIO Inc
NYSE:NIO
|
CN | |
Fluor Corp
NYSE:FLR
|
US | |
Jacobs Engineering Group Inc
NYSE:J
|
US | |
TopBuild Corp
NYSE:BLD
|
US | |
Abbott Laboratories
NYSE:ABT
|
US | |
Chevron Corp
NYSE:CVX
|
US | |
Occidental Petroleum Corp
NYSE:OXY
|
US | |
Matrix Service Co
NASDAQ:MTRX
|
US | |
Automatic Data Processing Inc
NASDAQ:ADP
|
US | |
Qualcomm Inc
NASDAQ:QCOM
|
US | |
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one ACLX stock under the Base Case scenario is 43.51 USD. Compared to the current market price of 90.84 USD, Arcellx Inc is Overvalued by 52%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Arcellx Inc
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for ACLX cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Economic Moat
Arcellx Inc
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Arcellx Inc
Balance Sheet Decomposition
Arcellx Inc
Current Assets | 587.3m |
Cash & Short-Term Investments | 574.3m |
Other Current Assets | 13m |
Non-Current Assets | 177.6m |
Long-Term Investments | 102.4m |
PP&E | 71.4m |
Other Non-Current Assets | 3.7m |
Current Liabilities | 137m |
Accounts Payable | 6m |
Accrued Liabilities | 50.3m |
Other Current Liabilities | 80.7m |
Non-Current Liabilities | 144.9m |
Other Non-Current Liabilities | 144.9m |
Earnings Waterfall
Arcellx Inc
Revenue
|
155.8m
USD
|
Operating Expenses
|
-225.2m
USD
|
Operating Income
|
-69.4m
USD
|
Other Expenses
|
29m
USD
|
Net Income
|
-40.4m
USD
|
Free Cash Flow Analysis
Arcellx Inc
USD | |
Free Cash Flow | USD |
ACLX Profitability Score
Profitability Due Diligence
Arcellx Inc's profitability score is 37/100. The higher the profitability score, the more profitable the company is.
Score
Arcellx Inc's profitability score is 37/100. The higher the profitability score, the more profitable the company is.
ACLX Solvency Score
Solvency Due Diligence
Arcellx Inc's solvency score is 77/100. The higher the solvency score, the more solvent the company is.
Score
Arcellx Inc's solvency score is 77/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
ACLX Price Targets Summary
Arcellx Inc
According to Wall Street analysts, the average 1-year price target for ACLX is 114.05 USD with a low forecast of 73.73 USD and a high forecast of 140.7 USD.
Dividends
Current shareholder yield for ACLX is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Ownership
ACLX Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Arcellx, Inc is a clinical-stage biotechnology company, which provides cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases. The company is headquartered in Gaithersburg, Maryland and currently employs 78 full-time employees. The company went IPO on 2022-02-04. The firm is focused developing controllable cell therapies for the treatment of patients with cancer and other incurable diseases. The firm is advancing its CART-ddBCMA product through its iMMagine Phase 2 pivotal trial in patients with relapsed or refractory (r/r) multiple myeloma (MM). The firm is also advancing ARC-SparX programs, ACLX-001 in r/r MM and ACLX-002 and ACLX-003 in r/r acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). ARC-SparX are adaptable versions of ddCARs where the antigen-targeting region is located on a SparX protein that can be dosed separately from the ARC-T cells, its D-Domain based universal CAR-T cells that are designed to activate only when bound to a SparX protein that is bound to an antigen on a cell. The company is also exploring indications in solid tumors.
Contact
IPO
Employees
Officers
The intrinsic value of one ACLX stock under the Base Case scenario is 43.51 USD.
Compared to the current market price of 90.84 USD, Arcellx Inc is Overvalued by 52%.